S&P 500   3,951.73 (+0.08%)
DOW   32,119.85 (+0.05%)
QQQ   308.64 (-0.36%)
AAPL   159.00 (+0.04%)
MSFT   277.88 (+0.08%)
META   204.79 (+0.25%)
GOOGL   104.73 (-0.82%)
AMZN   97.40 (-1.33%)
TSLA   188.41 (-1.98%)
NVDA   265.53 (-2.35%)
NIO   8.94 (-3.56%)
BABA   86.32 (-0.23%)
AMD   97.32 (-2.95%)
T   18.52 (+0.33%)
F   11.42 (+0.00%)
MU   60.59 (-1.22%)
CGC   1.92 (+0.26%)
GE   90.64 (-1.04%)
DIS   93.54 (-2.39%)
AMC   4.47 (+0.00%)
PFE   40.24 (+0.15%)
PYPL   73.23 (+0.92%)
NFLX   325.73 (+1.67%)
S&P 500   3,951.73 (+0.08%)
DOW   32,119.85 (+0.05%)
QQQ   308.64 (-0.36%)
AAPL   159.00 (+0.04%)
MSFT   277.88 (+0.08%)
META   204.79 (+0.25%)
GOOGL   104.73 (-0.82%)
AMZN   97.40 (-1.33%)
TSLA   188.41 (-1.98%)
NVDA   265.53 (-2.35%)
NIO   8.94 (-3.56%)
BABA   86.32 (-0.23%)
AMD   97.32 (-2.95%)
T   18.52 (+0.33%)
F   11.42 (+0.00%)
MU   60.59 (-1.22%)
CGC   1.92 (+0.26%)
GE   90.64 (-1.04%)
DIS   93.54 (-2.39%)
AMC   4.47 (+0.00%)
PFE   40.24 (+0.15%)
PYPL   73.23 (+0.92%)
NFLX   325.73 (+1.67%)
S&P 500   3,951.73 (+0.08%)
DOW   32,119.85 (+0.05%)
QQQ   308.64 (-0.36%)
AAPL   159.00 (+0.04%)
MSFT   277.88 (+0.08%)
META   204.79 (+0.25%)
GOOGL   104.73 (-0.82%)
AMZN   97.40 (-1.33%)
TSLA   188.41 (-1.98%)
NVDA   265.53 (-2.35%)
NIO   8.94 (-3.56%)
BABA   86.32 (-0.23%)
AMD   97.32 (-2.95%)
T   18.52 (+0.33%)
F   11.42 (+0.00%)
MU   60.59 (-1.22%)
CGC   1.92 (+0.26%)
GE   90.64 (-1.04%)
DIS   93.54 (-2.39%)
AMC   4.47 (+0.00%)
PFE   40.24 (+0.15%)
PYPL   73.23 (+0.92%)
NFLX   325.73 (+1.67%)
S&P 500   3,951.73 (+0.08%)
DOW   32,119.85 (+0.05%)
QQQ   308.64 (-0.36%)
AAPL   159.00 (+0.04%)
MSFT   277.88 (+0.08%)
META   204.79 (+0.25%)
GOOGL   104.73 (-0.82%)
AMZN   97.40 (-1.33%)
TSLA   188.41 (-1.98%)
NVDA   265.53 (-2.35%)
NIO   8.94 (-3.56%)
BABA   86.32 (-0.23%)
AMD   97.32 (-2.95%)
T   18.52 (+0.33%)
F   11.42 (+0.00%)
MU   60.59 (-1.22%)
CGC   1.92 (+0.26%)
GE   90.64 (-1.04%)
DIS   93.54 (-2.39%)
AMC   4.47 (+0.00%)
PFE   40.24 (+0.15%)
PYPL   73.23 (+0.92%)
NFLX   325.73 (+1.67%)
NASDAQ:NMTR

9 Meters Biopharma - NMTR Stock Forecast, Price & News

$1.32
+0.01 (+0.76%)
(As of 03/24/2023 01:39 PM ET)
Add
Compare
Today's Range
$1.31
▼
$1.34
50-Day Range
$1.31
▼
$2.61
52-Week Range
$1.00
▼
$13.20
Volume
11,826 shs
Average Volume
104,928 shs
Market Capitalization
$17.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.85

9 Meters Biopharma MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
3,246.6% Upside
$44.18 Price Target
Short Interest
Healthy
3.13% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.48mentions of 9 Meters Biopharma in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.28) to ($3.10) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

488th out of 989 stocks

Pharmaceutical Preparations Industry

228th out of 480 stocks

See Top Rated MarketRank™ Stocks Here

NMTR stock logo

About 9 Meters Biopharma (NASDAQ:NMTR) Stock

9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS), celiac disease, and three early-stage candidates for undisclosed rare diseases and/or unmet needs. The company is founded by Jay P. Madan and Kendyle Woodard in 2012 and is headquartered in Raleigh, NC.

Receive NMTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 9 Meters Biopharma and its competitors with MarketBeat's FREE daily newsletter.

NMTR Stock News Headlines

March 24, 2023 | americanbankingnews.com
9 Meters Biopharma's (NMTR) "Buy" Rating Reaffirmed at Brookline Capital Management
March 22, 2023 | benzinga.com
9 Meters Biopharma Stock (NASDAQ:NMTR), Guidance and Forecast
March 24, 2023 | Behind the Markets (Ad)
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
March 20, 2023 | americanbankingnews.com
9 Meters Biopharma (NASDAQ:NMTR) Stock Rating Lowered by Truist Financial
March 20, 2023 | americanbankingnews.com
9 Meters Biopharma (NMTR) Set to Announce Quarterly Earnings on Tuesday
March 16, 2023 | bizjournals.com
Raleigh pharma raises $5M as phase 3 study begins
March 15, 2023 | finance.yahoo.com
9 Meters Biopharma Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
March 14, 2023 | finance.yahoo.com
9 Meters Biopharma Announces $5 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules
March 24, 2023 | Behind the Markets (Ad)
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
March 7, 2023 | finance.yahoo.com
9 Meters Biopharma to Present at the Oppenheimer 33rd Annual Healthcare Conference
January 31, 2023 | finance.yahoo.com
9 Meters Biopharma to Present at the 2023 BIO CEO & Investor Conference
November 29, 2022 | finance.yahoo.com
9 Meters Biopharma Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome
November 14, 2022 | finance.yahoo.com
9 Meters Biopharma Announces Continued Immuno-Oncology Collaboration with Gustave Roussy
November 8, 2022 | finance.yahoo.com
9 Meters Biopharma Provides Business Update and Reports Financial Results for Third Quarter 2022
October 24, 2022 | finance.yahoo.com
9 Meters Biopharma Presents Preclinical Data on Glucose-Dependent Insulinotropic Polypeptide (GIP) Monoclonal Antibodies for Obesity at the American College of Gastroenterology 2022 Annual Scientific Meeting
October 18, 2022 | bizjournals.com
9 Meters Biopharma triggers reverse stock split to maintain Nasdaq listing
October 18, 2022 | finance.yahoo.com
9 Meters Biopharma to Present at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
October 17, 2022 | finance.yahoo.com
9 Meters Biopharma Announces 1-for-20 Reverse Stock Split
September 27, 2022 | seekingalpha.com
9 Meters Biopharma gains after mid-stage data for short bowel syndrome drug
September 26, 2022 | finance.yahoo.com
9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA for Vurolenatide in Short Bowel Syndrome
September 6, 2022 | finance.yahoo.com
9 Meters Biopharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 1, 2022 | finance.yahoo.com
9 Meters Biopharma to Participate at the 44th European Society for Clinical Nutrition and Metabolism (ESPEN) Congress
August 31, 2022 | finance.yahoo.com
9 Meters Biopharma to Participate in the Citi 17th Annual BioPharma Conference
August 13, 2022 | uk.finance.yahoo.com
9 Meters Biopharma, Inc. (NMTR)
July 6, 2022 | finance.yahoo.com
9 Meters Biopharma to Participate in the William Blair Biotech Focus Conference 2022
July 5, 2022 | bizjournals.com
Raleigh drugmaker shifts focus after trial setback
June 30, 2022 | seekingalpha.com
9 Meters stock falls despite drug showing promise in short bowel syndrome trial
See More Headlines
Receive NMTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 9 Meters Biopharma and its competitors with MarketBeat's FREE daily newsletter.

NMTR Company Calendar

Last Earnings
11/15/2021
Today
3/24/2023
Next Earnings (Estimated)
3/24/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NMTR
CUSIP
N/A
CIK
1551986
Web
www.9meters.com
Phone
(919) 275-1933
Fax
N/A
Employees
21
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$44.18
High Stock Price Forecast
$100.00
Low Stock Price Forecast
$1.70
Forecasted Upside/Downside
+1,491.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($3.12)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-36,780,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-153.18%
Return on Assets
-101.53%

Debt

Debt-to-Equity Ratio
1.17
Current Ratio
1.43
Quick Ratio
1.43

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.25 per share
Price / Book
0.40

Miscellaneous

Outstanding Shares
12,950,000
Free Float
12,644,000
Market Cap
$16.96 million
Optionable
Optionable
Beta
0.51

Key Executives

  • John TemperatoJohn Temperato
    President, Chief Executive Officer & Director
  • Sireesh Appajosyula
    SVP-Corporate Development & Operations
  • Bethany L. Sensenig
    Chief Financial & Accounting Officer
  • Patrick H. Griffin
    Chief Medical Officer
  • Sarah Liu
    Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













NMTR Stock - Frequently Asked Questions

Should I buy or sell 9 Meters Biopharma stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 9 Meters Biopharma in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NMTR shares.
View NMTR analyst ratings or view top-rated stocks.

What is 9 Meters Biopharma's stock price forecast for 2023?

6 brokers have issued 12-month price targets for 9 Meters Biopharma's stock. Their NMTR share price forecasts range from $1.70 to $100.00. On average, they anticipate the company's stock price to reach $44.18 in the next twelve months. This suggests a possible upside of 3,272.1% from the stock's current price.
View analysts price targets for NMTR or view top-rated stocks among Wall Street analysts.

How have NMTR shares performed in 2023?

9 Meters Biopharma's stock was trading at $1.26 at the beginning of 2023. Since then, NMTR stock has increased by 4.0% and is now trading at $1.31.
View the best growth stocks for 2023 here.

When is 9 Meters Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 24th 2023.
View our NMTR earnings forecast.

How were 9 Meters Biopharma's earnings last quarter?

9 Meters Biopharma, Inc. (NASDAQ:NMTR) announced its quarterly earnings data on Monday, November, 15th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by $0.26.

When did 9 Meters Biopharma's stock split?

9 Meters Biopharma shares reverse split on Tuesday, October 18th 2022. The 1-20 reverse split was announced on Tuesday, October 18th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of 9 Meters Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other 9 Meters Biopharma investors own include Acasti Pharma (ACST), Miragen Therapeutics (MGEN), Bionano Genomics (BNGO), Evofem Biosciences (EVFM), Outlook Therapeutics (OTLK), Tonix Pharmaceuticals (TNXP), Alibaba Group (BABA), Cellectar Biosciences (CLRB), Pfizer (PFE) and Soleno Therapeutics (SLNO).

What is 9 Meters Biopharma's stock symbol?

9 Meters Biopharma trades on the NASDAQ under the ticker symbol "NMTR."

Who are 9 Meters Biopharma's major shareholders?

9 Meters Biopharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Laurion Capital Management LP (1.76%), GSA Capital Partners LLP (0.85%), Geode Capital Management LLC (0.84%), Renaissance Technologies LLC (0.57%), Two Sigma Investments LP (0.37%) and ODonnell Financial Services LLC (0.34%). Insiders that own company stock include Edward J Sitar, Israel Gp Ltd Orbimed, John Temperato, Mark A Sirgo and Michael T Constantino.
View institutional ownership trends.

How do I buy shares of 9 Meters Biopharma?

Shares of NMTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is 9 Meters Biopharma's stock price today?

One share of NMTR stock can currently be purchased for approximately $1.31.

How much money does 9 Meters Biopharma make?

9 Meters Biopharma (NASDAQ:NMTR) has a market capitalization of $16.96 million. The company earns $-36,780,000.00 in net income (profit) each year or ($3.12) on an earnings per share basis.

How can I contact 9 Meters Biopharma?

9 Meters Biopharma's mailing address is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. The official website for the company is www.9meters.com. The company can be reached via phone at (919) 275-1933 or via email at investor-relations@9meters.com.

This page (NASDAQ:NMTR) was last updated on 3/24/2023 by MarketBeat.com Staff